Introducing FirePlex®-HT High-Throughput Multiplex Immunoassays – Delivering More Data from Precious Samples
| Cambridge, UK – FirePlex®-HT Immunoassays offer a no-wash workflow in 384-well plate format, enabling multiplex quantification of up to 10 protein analytes per well from as little as 6.25 ul of plasma, serum, or cell culture supernatant. A 2-step protocol limits hands-on time and can be easily automated, making the assay well-suited to high-throughput studies.
Data from FirePlex particles can be collected using any high-content imager at scan speeds of less than 20 minutes per plate. Subsequent analysis is performed using Abcam’s free integrated FirePlex® Analysis Workbench software. Available as pre-designed panels or user-designed custom panels, researchers can select from a growing catalog of over 800 antibody pairs, the majority of which have been developed using Abcam’s recombinant monoclonal antibody technology. Quality antibodies combined with FirePlex particles enable consistent assays with a dynamic range of 3-4 logs, sensitivity down to 1 pg/ml, and <15% intra-plate CVs. Abcam’s Fireplex-HT immunoassays are available through an Early Adopter Program. To find out more visit, www.abcam.com/fireplex About Abcam Already a pioneer in data sharing and ecommerce in the life sciences, Abcam’s ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health. Two-thirds of the world’s 750,000 life science researchers use Abcam’s affinity binders, reagents, biomarkers and assays and the Company’s products are mentioned in over 20,000 of the 56,000 peer-reviewed papers published each year in the life sciences. By actively listening to and collaborating with researchers, the Company continuously advances its portfolio to address their needs. A transparent programme of customer reviews and datasheets, combined with an industry-leading validation initiative, gives researchers increased confidence in their results. Abcam’s eleven locations are in the world’s leading life science research hubs, enabling local services and multi-language support. Founded in 1998 and headquartered in Cambridge, UK, the Company sells to more than 130 countries. Abcam was admitted to AIM in 2005 (AIM: ABC). To find out more, please visit www.abcam.com |
